Lantern Pharma appoints Lee T. Schalop to Board, reduces shareholder quorum to 33.33%

Lantern Pharma Inc.

Appointed Lee T. Schalop, M.D., former CEO of Oncoceutics (sold to Chimerix for $450M), to the Board effective July 24, 2025.
Dr. Schalop has extensive biotech and finance background including roles at Morgan Stanley, J.P. Morgan, Credit Suisse.
Board amended By-laws to reduce stockholder quorum requirement from majority to one-third (33.33%) of shares entitled to vote.
Amendment to Section 2.07 effective immediately on July 24, 2025.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Lantern Pharma Inc.: Reduced quorum requirement for stockholder meetings from a majority to one-third (33.33%) of shares entitled to vote (effective 2025-07-24).

Change: bylaw amendment
Effective: 2025-07-24

Exact text from the filing

On July 24, 2025, the Board approved an amendment to the Company’s By-laws (the “By-laws”), effective immediately. The amendment modified the provisions for determining a quorum for a meeting of stockholders of the Company and effectively reduced the quorum requirement from a majority of the shares entitled to vote at the meeting to one-third (33.33%) of the shares entitled to vote at the meeting.

View on SEC.gov

Browse all governance changes →

Lantern Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-021407

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.